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Clinical Practice Points 
 A 65-year-old man patient presented to us with 2-month history of perineal irritation, dysuria, and 
nicturia. 
 The diagnosis revealed a case of signet-ring cell mucinous adenocarcinoma of the prostate with massive 
local extension and a good response to biochemotherapy after bone skeletal progression. 
 Here, we discuss the clinical features and therapy response, which were similar to those of metastatic 
colorectal carcinoma. 
 Treatment with FOLFOX + Erbitux (after K-ras typing) seems to be effective (completely response) with 
acceptable treatment-related morbidity for this rare prostate cancer subtype. 
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Introduction 
Carcinoma of the prostate gland is the most common visceral malignant tumor that affects 
men.
1
 Conventional acinar adenocarcinoma represents the majority (>90%) of the tumors derived 
from the prostate gland. Uncommon variants (5%-10%) of prostatic adenocarcinoma are readily 
recognizable by their distinctive histologic features and are important because they might signify a 
worse clinical prognosis.
2
 
 
Primary signet ring cell carcinomas (SRCC) of the prostate are extremely rare. As the name 
implies, the defining characteristic of the variant is the presence of signet ring cells, which are 
characterized by a crescent-shaped nucleus that is indented, displaced, and compressed against the 
cell membrane by a large, clear, cytoplasmic vacuole.
2
 Fewer than 60 patients with this rare 
malignancy have been described in the literature. SRCC of the prostate exhibits a median overall 
survival of 28 months from initial surgery, which implies a worse prognosis compared with 
standard adenocarcinomas.
3
 
Case Report 
A 65-year-old man with an Eastern Cooperative Oncology Group status of 0 at baseline and no 
relevant medical history visited the hospital due to a 2-month history of perineal irritation, dysuria, 
and nycturia. After digital rectal examination and sextant needle biopsy, the patient was diagnosed 
with low-differentiated mucinous adenocarcinoma; >50% of the cells were signet ring cells 
(T3bN0M0). The Gleason grade was IX (IV + V). The carcinoma cells were positive for prostate-
specific antigen (PSA), cytokeratin (CK) 20 (CK20), and alcian blue stain. CK5 and CK6 were 
negative. Levels of serum markers were as follows: PSA/soluble, 6.6 ng/mL (reference range, 0.0-
4.0 ng/mL); PSA/free, 1.9 ng/mL; PSA/complexed, 3.5 ng/mL, PSA-free–PSA-soluble ratio, 0.29, 
and carcinoembryonic antigen (CEA), 3.40 ng/mL (reference range, 0.0-5.0 ng/mL). A whole-
body computed tomography showed a partially calcified prostatic mass that infiltrated the 
trigonous and lateral bladder walls and probably the seminal vesicles. The prostatic mass induced 
bilateral obstructive uropathy. Magnetic resonance imaging of the prostate was performed, and a 
diffuse pattern was interpreted as generalized tumor infiltration of the whole gland, including both 
seminal vesicles. The patient also underwent a full workup, including colonoscopy and oral 
endoscopy, with biopsy specimens negative for neoplasia. 
 
Five cycles of neoadjuvant prostate cancer common chemotherapy with docetaxel (docetaxel, 
75 mg/m
2
 every 3 weeks plus prednisone 10 mg/d) were administered before radical surgery. After 
systemic treatment, a minor response of the prostate gland was observed by magnetic resonance 
imaging (the normal rectal wall and the small prostate were completely separated from the 
rectum). The PSA level after chemotherapy was ≥4 ng/mL, and was negative. The patient 
underwent radical cystoprostatectomy. Histologic examination of 1 section showed infiltration by 
a population of uniform, plump, mucus-containing cells with eccentrically compressed 
hyperchromatic nuclei, and positivity to periodic acid–Schiff and alcian blue stain (signet ring 
cells) (Figure 1). 
  
 
 
 
Figure 1. Sections that correspond to infiltrating adenocarcinoma of signet ring cells in the prostate (Hematoxylin and 
Eosin; original magnifications, ×100, ×400) 
After radical surgery, the patient had no evidence of disease and had a good quality of life. 
Over the next 8 months, the patient experienced diffuse bone pain and had elevated serum alkaline 
phosphatase levels. Serum PSA and prostatic acid phosphatase were negative, but CEA was 
positive (859 ng/mL). Serum testosterone levels were 44 ng/mL (limits, 241-827 ng/mL). Bone 
scan scintigraphy revealed extensive skeletal involvement (Figure 2). A computed tomography did 
not show locoregional (nearby pelvic structures) or visceral and/or node involvement, but 
metastatic blastic lesions were observed on axial and appendicular bones. 
 
 
 
Figure 2. Evolution of metastatic bone disease after initiation of cytostatic treatment 
  
We assessed the mutational status for mutation of KRAS by polymerase chain reaction, which 
showed no mutation in exons 12 and 13, or 61, which are most commonly mutated in colorectal 
cancer. Based on this information, we decided to start systemic cytostatic treatment with FOLFOX 
(oxaliplatin 85 mg/m
2
 on day 1, plus leucovorin 200 mg/m
2
 and fluorouracil as a 400 mg/m
2
 bolus, 
followed by a 600 mg/m
2
 infusion during 22 hours on days 1 and 2) plus Erbitux (500 mg/m
2
 day 
1)
4
; we obtained a partial response after 3 cycles and a complete response after 7 cycles, as 
determined by bone scan scintigraphy images (Figure 2). Therapy was discontinued due to 
peripheral neurotoxicity of oxaliplatin. Twelve months after the start of treatment, CEA levels had 
normalized (<5 ng/mL). 
Discussion 
Primary SRCC is a rare disease that was first described in 1985 and is estimated to occur in 30 
of every 100,000 cases of prostate cancer.
5
 The diagnosis of primary prostatic SRCC requires that 
25% or more of the tumor be composed of signet ring cells.
6
 
 
There is a lack of data regarding the molecular etiology of signet ring cells.
7
 In signet ring cell 
adenocarcinomas of the colon, a higher frequency of BRAF mutations (22% vs. 8.6%) and a lower 
frequency of KRAS mutations were observed.
8,9
 Based on these data, the authors concluded that 
SRCCs might have a distinct mutation pattern with respect to the main growth kinase pathways. 
The higher incidence of this type of tumor in the digestive tract and the lack of activity when 
docetaxel-based chemotherapy was administered as neoadjuvant treatment compelled us to treat 
this patient from a molecular and histologic perspective rather than an organ-derived perspective. 
 
Primary SRCCs of the prostate are very rare and have a poor prognosis even when treated with 
aggressive therapy. More of these patients present with stage IV disease than with any other stage. 
Patients in most of the reported cases received typical treatment for prostatic adenocarcinoma, 
including hormonal manipulation, surgery, radiation, or a combination. SRCC of the prostate 
rarely responds to hormonal manipulation.
5
 Elevation of PSA levels as a tumor marker for SRCC 
of the prostate has not been consistently observed in the literature. To the best of our knowledge, 
the present case is the first SRCC of the prostate to be treated with colorectal chemotherapy. This 
approach achieved a near-complete response and evident clinical benefit, as is shown in Figure 2. 
 
In summary, treatment of SRCC of the prostate with FOLFOX plus cetuximab seems to be 
effective, with acceptable treatment-related morbidity for this rare prostate cancer subtype. The 
lack of clinical data in this setting is justified by the lower incidence of the disease, but cooperative 
organization, therefore, is mandatory. Adding molecular techniques to routine pathologic stains 
may orientate treatment according to druggable targets available in the market, this is critical for 
patient management, especially with rare and aggressive malignancies such as SRCC of the 
prostate. 
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